JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Optimizing and Validating Systemic DNA Damage Response Profiling to Predict Neoadjuvant Chemoradiation Response in Rectal Cancer

Medrxiv : the Preprint Server for Health Sciences +

|

November 28, 2024

|

November 28, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study developed a new blood test measuring DNA damage response (DDR) proteins to predict treatment response in locally advanced rectal cancer (LARC) patients receiving neoadjuvant chemoradiation therapy (nCRT). This allows for personalized treatment strategies, improving efficacy and reducing toxicity.

Area Of Science

  • Oncology
  • Molecular Biology
  • Clinical Diagnostics

Background

  • Locally advanced rectal cancer (LARC) treatment involves neoadjuvant chemoradiation therapy (nCRT), but patient response varies significantly.
  • Identifying non-responders to nCRT is crucial to avoid ineffective treatment and associated toxicities.
  • Personalized medicine approaches are needed to optimize treatment selection for LARC patients.

Purpose Of The Study

  • To develop and validate a predictive assay for nCRT response in LARC patients.
  • To stratify LARC patients based on DNA damage response (DDR) proteins in peripheral blood monocytes (PBMCs).
  • To establish a framework for predicting nCRT response using a novel blood assay.

Main Methods

  • Collected PBMCs from LARC patients before and after nCRT, categorized by neoadjuvant rectal (NAR) score.
  • Assessed DDR using immunofluorescence (γH2AX foci) and Luminex xMAP assay for multiple DDR proteins (Chk1, Chk2, γH2AX, p53, ATR, MDM2, p21).
  • Validated assay performance and analyzed clinical associations between DDR protein levels and treatment response.

Main Results

  • PBMCs from poor responders showed significantly lower γH2AX foci compared to complete responders (p<0.0001).
  • The xMAP assay demonstrated high precision, reproducibility, and linearity.
  • Six DDR proteins (ATR, MDM2, Chk1, Chk2, γH2AX, p53) significantly differentiated complete responders from poor responders (p ≤ 1e-5).

Conclusions

  • An optimized assay can assess DDR proteins in PBMCs to predict nCRT response in LARC patients.
  • Specific protein thresholds identified accurately segregate responders from non-responders.
  • This predictive assay supports personalized oncology by optimizing treatment efficacy and minimizing toxicity.